Skip to content
value.today

Lifeward Ltd.

LFWD
$17 Mmarket cap on Oct 29, 2026-72.5% since Jan 2024
Compare
World rank
#24,829
Revenue
$22 M
For year ending December-2025
Net income
$-20 M
-90.4% margin
SEC filing
Employees
81
As of December 31, 2025
value.today research

Lifeward Ltd. in brief

Lifeward Ltd. is a listed company in the Medical Devices industry, based in Israel. Its market value was $17 M on 29 October 2026, which makes it the 24,829th largest listed company in the world and the 257th largest in Israel on this site. In the year to December 2025 it had sales of $22 M and a net loss of $20 M. It employs about 81 people. Its largest product and service lines by sales in 2025 were Service and warranty (14%) and Lease Of Products (8%). By market, the largest shares of its 2025 sales came from USA (60%), Germany (18%) and Europe (13%). Its shares trade under the symbol LFWD (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Lifeward Ltd.

We are a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering proven functional and health benefits in clinical settings as well as in the home and community. Our initial product offerings were the ReWalk Personal and ReWalk Rehabilitation Exoskeleton devices for individuals with spinal cord injury. These devices are robotic exoskeletons that are designed for individuals with paraplegia that use our patented tilt-sensor technology and an onboard computer and motion sensors to drive motorized legs that power movement. These SCI Products allow individuals with spinal cord injury the ability to stand and walk again during everyday activities at home or in the community. In March 2023, we received clearance of our premarket notification (“510(k)”) from the U.S. Food and Drug Administration for the ReWalk Personal Exoskeleton with stair and curb functionality, which adds usage on stairs and curbs to the indication for use for the device in the U.S. The clearance permits U.S. customers to participate in more walking activities in real-world environments in their daily lives where stairs or curbs may have previously limited them when using the exoskeleton for its intended, FDA-indicated uses. This feature has been available in Europe since initial CE Clearance, and real-world data from a cohort of 47 European users throughout a period of over seven years consisting of over 18,000 stair steps, were collected to demonstrate the safety and efficacy of this feature and support the FDA submission. In March 2025, we received 510(k) clearance from the U.S. Food and Drug Administration for the ReWalk 7 Personal Exoskeleton device, a next-generation ReWalk model.

Lifeward Ltd. timeline

5 events, 2014–2024
  1. 2014
  2. 🔔
    · approximate
    Initial public offering on Nasdaq
  3. ✎
    Renamed ReWalk Robotics Ltd.
    Formerly Argo Medical Technologies Ltd..
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2024
  6. 💰
    Record revenue of $26 million
    FY2024, the highest of the 8 years on record.
  7. ✎
    Renamed Lifeward Ltd.
    Formerly ReWalk Robotics Ltd..

Events of Lifeward Ltd. from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$21 M$41 M$62 M$82 M2020202120222023202420252026

World rank over time

▲ up 520 places since 2020
2020-01-01: #25366#25,36620202021-01-01: #22139#22,13920212022-01-07: #24515#24,51520222022-12-25: #25351#25,35120222023-07-30: #26051#26,05120232024-01-05: #23973#23,97320242026-10-14: #24722#24,72220262026-10-29: #24846#24,8462026

Rank in Israel: #337 (Jan 2020) · #314 (Jan 2021) · #337 (Jan 2022) · #307 (Dec 2022) · #348 (Jul 2023) · #310 (Jan 2024) · #256 (Oct 2026) · #257 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.8×
Price / book
2.0×
Free cash flow yield
-100.6%
Net margin (TTM)
-141.3%
Operating margin
-89.3%
Return on equity
-366.6%
Liabilities / assets
63.3%
Net debt
$-15M
Revenue growth
-14.1%
R&D / revenue
14.8%
Revenue per employee
$272 K
Profit per employee
$-246 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $7M, net income $-22M$7MFY18Fiscal year ending Dec 2019: revenue $5M, net income $-16M$5MFY19Fiscal year ending Dec 2020: revenue $4M, net income $-13M$4MFY20Fiscal year ending Dec 2021: revenue $6M, net income $-13M$6MFY21Fiscal year ending Dec 2022: revenue $6M, net income $-20M$6MFY22Fiscal year ending Dec 2023: revenue $14M, net income $-22M$14MFY23Fiscal year ending Dec 2024: revenue $26M, net income $-29M$26MFY24Fiscal year ending Dec 2025: revenue $22M, net income $-20M$22MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$22M-14.1%$-20M$-20M-90.4%
Dec 2024$26M+85.3%$-29M$-29M-112.8%
Dec 2023$14M+151.4%$-24M$-22M-159.8%
Dec 2022$6M-7.7%$-19M$-20M-355.2%
Dec 2021$6M+36.0%$-13M$-13M-213.4%
Dec 2020$4M-9.9%$-12M$-13M-295.7%
Dec 2019$5M-25.5%$-14M$-16M-319.3%
Dec 2018$7M—$-19M$-22M-331.5%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-17M$0M$-17M$-17.16—
Dec 2024$-22M$0M$-22M$-39.96—
Dec 2023$-21M$0M$-21M$-31.13—
Dec 2022$-18M$0M$-18M$-2.20—
Dec 2021$-11M$0M$-12M$-0.27—
Dec 2020$-13M$0M$-13M$-0.82—
Dec 2019$-15M$0M$-15M$-2.70—
Dec 2018$-15M$0M$-15M$-14.72—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$22M
Net income, trailing 12 months
$-31M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $8M, net income $-15M$8MDec ’24Three months to Mar 2025: revenue $5M, net income $-5M$5MMar ’25Three months to Jun 2025: revenue $6M, net income $-7M$6MJun ’25Three months to Sep 2025: revenue $6M, net income $-3M$6MSep ’25Three months to Dec 2025 (from the annual report): revenue $5M, net income $-5M$5MDec ’25Three months to Mar 2026: revenue $4M, net income $-11M$4MMar ’26Three months to Jun 2026: revenue $7M, net income $-12M$7MJun ’26Three months to Sep 2026: revenue $5M, net income $-5M$5MSep ’26

Latest quarter to Sep 2026: revenue $5M (-12.4% on a year earlier), net income $-5M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Lifeward Ltd. with the US Securities and Exchange Commission.

Annual results

Revenue
$22 M
Operating income
$-20 M
Net income
$-20 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$23 M
Total liabilities
$14 M
Total equity
$8 M

As of December-2025

Top 11 institutional investors in Lifeward Ltd.#

As of Sep 30, 2026
11 institutions held 17,066 shares (about 0.6% of the shares outstanding) on Sep 30, 2026. The ten largest hold 0.6%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 11 largest institutional investors in Lifeward Ltd.
#InstitutionShares heldChange (shares)% heldValueFiled
1Renaissance Technologies LLC10,727-600 (-5.30%)0.38%$0 MNov 12, 2026
2Tower Research Capital LLC (TRC)3,040New0.11%$0 MNov 16, 2026
3UBS Group AG1,952-200 (-9.29%)0.07%$0 MNov 10, 2026
4Citigroup Inc518New0.02%$0 MNov 4, 2026
5Morgan Stanley334+60 (+21.90%)0.01%$0 MNov 13, 2026
6Osaic Holdings, Inc.226+119 (+111.21%)0.01%$0 MNov 12, 2026
7SBI Securities Co., Ltd.1960 (0.00%)0.01%$0 MOct 22, 2026
8Royal Bank Of Canada500 (0.00%)0.00%$0 MNov 16, 2026
9National Bank Of Canada /fi/110 (0.00%)0.00%$0 MNov 16, 2026
10Caitong International Asset Management Co., Ltd7+3 (+75.00%)0.00%$0 MOct 29, 2026
11Kiker Wealth Management, LLC5New0.00%$0 MNov 16, 2026

Mutual funds holding Lifeward Ltd.#

3 funds hold shares worth $0 M (about 0.0% of the company). Since their previous reports 2 added shares and 0 sold, buying $0 M net.
Mutual funds holding Lifeward Ltd.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP804$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC216$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP97$0 M<0.01%<0.01%newJul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 3 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Lifeward Ltd.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
42
since
$105 K-$1.7 M$0Nov 2023: bought $90 K (3 trades), sold $0 (0 trades)Nov 23May 2024: bought $50 K (3 trades), sold $8 K (1 trades)Jun 2024: bought $0 (0 trades), sold $15 K (1 trades)JunJul 2024: bought $0 (0 trades), sold $7 K (1 trades)Aug 2024: bought $0 (0 trades), sold $17 K (2 trades)AugSep 2024: bought $0 (0 trades), sold $14 K (2 trades)Nov 2024: bought $105 K (3 trades), sold $0 (0 trades)NovDec 2024: bought $10 K (1 trades), sold $7 K (1 trades)Jan 2025: bought $0 (0 trades), sold $1.7 M (4 trades)Jan 25May 2025: bought $0 (0 trades), sold $2 K (1 trades)Sep 2025: bought $0 (0 trades), sold $1 K (1 trades)Sep
Bought (open market)Sold (open market)Hover a month for the totals
Lifeward Ltd.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Avraham GabayDirectorGrant or award+13,643——13,643Form 4
filed Haggai ZamirDirectorGrant or award+6,711——6,711Form 4
filed Yonason GreenwaldDirectorGrant or award+6,711——6,711Form 4
filed Keith Dale RoseChief Medical OfficerGrant or award+15,000——17,083Form 4
filed William Mark SigsbeeDirectorGrant or award+11,485——11,485Form 4
filed Moshe H. RozenbaumDirectorGrant or award+11,485——11,485Form 4
filed Yehuda ReznickDirectorGrant or award+7,657——7,657Form 4
filed Nadav KidronDirectorGrant or award+7,657——7,657Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Lifeward Ltd.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
87,325
5.7% of shares · 5.01 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 18-for-1 split in the period to ; 1-for-18 reverse split

Trading halts

  • 2026-10-01 13:38 UTC, code LUDP, resumed 13:43 UTC
  • 2026-02-24 00:50 UTC, code T3, resumed 14:00 UTC
  • 2026-01-13 12:55 UTC, code T3, resumed 13:30 UTC
  • 2025-03-13 13:32 UTC, code LUDP, resumed 13:37 UTC

Fails to deliver

  • : 35 shares at $5.90
  • : 110 shares at $6.02
  • : 110 shares at $5.93
  • : 641 shares at $5.91
  • : 726 shares at $6.17

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Lifeward Ltd. scorecard#

Passes 6 of the 20 checks that could be worked out: strongest in valuation (2 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median2.0×Price to book 2.0× against Medical Devices's median of 2.5×.
    • ✓Price to sales below its peers' median0.8×Price to sales 0.8× against Medical Devices's median of 2.4×.
    • ✗Free cash flow yield above 5%-100.6%Free cash flow is -100.6% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✗Revenue grew in the newest year-14.2%Revenue down 14.2% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years58.7%58.7% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median58.7%58.7% a year against Medical Devices's median of 10.8% (73 companies).
    • ✗Earnings per share grew in the newest year-17.16 vs -39.96Diluted EPS -17.16 in fiscal 2025 against -39.96 the year before (report's currency).
    • ✗Net income higher than five years earlier-$20 M-$20 M in fiscal 2025 against -$13 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$20 MNet income -$20 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-89.3%-89.3% against Medical Devices's median of -8.2% (86 companies).
    • ✗Return on equity above 15%-146.1%-146.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-89.3%-89.3% in fiscal 2025 against -346.6% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.3×Current ratio 1.31 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-18.39Z-score -18.39 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year60.4%Diluted shares up 60.4% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Lifeward Ltd.'s statements, beside the median of Medical Devices.

Lifeward Ltd.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-89.3%-8.2%
Net margin-90.4%-10.4%
Return on equity-146.1%-16.8%
Revenue growth, 3 years a year58.7%10.8%
Revenue growth-14.2%10.4%
Free cash flow margin-76.5%-1.9%

4of 8on the Piotroski tests of financial strength

  • Revenue fell 14.2% against the year before.
  • Net loss of $20 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$17 million.
  • The share count rose 60.4% in the year.

Lifeward Ltd.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Lifeward Ltd.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue2226145.56.04.44.96.57.85.9
Cost of revenue14179.43.63.12.22.13.74.75.1
Gross profit8.48.24.51.92.92.22.72.83.10.7
Research and development3.24.64.14.02.93.55.37.36.09.0
Selling and marketing1418149.87.05.86.27.91114
General and administrative8.25.210.07.15.65.05.36.87.78.2
Operating expenses28382821161417222531
Operating income−20−29−24−19−13−12−14−19−22−30
Interest expense and finance costs————00.91.5r—2.52.0
Net interest income−0.30.6r1.4r00—————
Income before tax−20−29−22−19−13−13−16−22−25−33
Income tax−0.10.0−0.00.50.10.10.0−0.00.10.0
Net income including minority interests20——−20−13−13−16−22−25−33
Net income attributable to shareholders−20−29−22−20−13−13−16−22−25−33
Earnings per share, basic-17.16-39.96r-31.13r-2.20r-0.27-0.82-2.70-14.72r-30.57r-2.47
Earnings per share, diluted-17.16-39.96r-31.13r-2.20r-0.27-0.82-2.70-14.72r-30.57r-2.47
Shares, weighted average (basic)1.20.7r0.7r8.9r4816————
Shares, weighted average (diluted)1.20.7r0.7r8.9r48165.81.5r0.8r13
Balance sheet
Cash and cash equivalents2.26.728688820169.51524
Receivables6.16.03.11.00.60.70.80.81.11.3
Inventory5.76.75.72.93.03.53.12.23.63.3
Other current assets0.40.3r0.7r0.2r0.1r0.0r0.2r0.70.5r0.7r
Current assets16213973932521132129r
Property, plant and equipment0.60.91.30.20.30.40.50.60.81.3
Right-of-use (leased) assets1.50.51.90.80.91.31.7———
Goodwill4.87.57.50——————
Other intangible assets—013———————
Non-current assets7.19.2241.72.22.83.31.71.92.4r
Total assets23306374952824152332
Accounts payable5.65.05.12.01.42.32.72.31.83.4
Debt due within a year——————5.41.76.47.5
Current liabilities1210124.84.04.7105.49.712
Long-term debt——————1.57.08.911
Lease liabilities (non-current)1.20.00.60.30.40.91.3———
Non-current liabilities2.51.44.91.31.31.63.47.69.411
Total liabilities1412176.15.46.314131924
Retained earnings−285−265−236−214−194−181−168−153−131−106
Shareholders' equity8.41947688922111.93.78.3
Total liabilities and equity23306374952824152332
Shares outstanding1.50.7r8.6r6062257.32.8r3016
Cash-flow statement
Depreciation and amortization————————0.60.7
Share-based compensation0.71.31.31.00.80.71.12.83.73.4
Cash from operating activities−17−22−21−18−11−13−15−15−22r−27r
Capital expenditure−0.00−0.1−0.0−0.0−0.1−0.0−0.0−0.0−0.5
Acquisitions, net of cash acquired00−1800—————
Cash from investing activities−0.00−18−0.0−0.0−0.1−0.0−0.0−0.0−0.4
Debt issued1.400000.4——020
Debt repaid———00−7.0−1.7−3.9−3.1−0.9
Shares issued———————1.19.34.1
Cash from financing activities120−1.0−2.58017219.71334
Exchange-rate effect on cash—0.00.0−0.100————
Change in cash−4.5−22−40−20684.1——−9.15.8
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Lifeward Ltd. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Sale of product(total)$17 M78%
  • Service and warranty$3 M14%
  • Lease Of Products$2 M8.1%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Lifeward Ltd. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Lifeward Ltd.: countries of operation
CountryPresenceRevenue there
🇮🇱 IsraelHeadquarters—
🇺🇸 USA1 office$13 M60%
🇩🇪 Germany$4 M18%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Lifeward Ltd.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$835 K
Other top executives, average
—
$100 invested is now
$11
Lifeward Ltd.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$835 K$621 K—$11
2024Chief executive$473 K$279 K—$33
2023Chief executive$889 K$861 K—$63

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Lifeward Ltd.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 2 · Acquisition or sale completed 1 · Directors and officers 13 · Material agreement 4 · New debt 4 · Unregistered share sale 5 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 4 · Results announced 6

Lifeward Ltd.: events reported to the SEC
FiledWhat happenedFiling
Shareholder vote8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Directors and officersResults announced8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Acquisition or sale completedDirectors and officersUnregistered share sale8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Directors and officers8-K
Unregistered share sale8-K
Material agreementNew debt8-K
Directors and officersShareholder vote8-K
Directors and officersMaterial agreementNew debtUnregistered share sale8-K
Shareholder vote8-K
Directors and officers8-K
Material agreementNew debtUnregistered share saleResults announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Delisting notice8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

How Lifeward Ltd. compares in Medical Devices

  • Market cap$17 M · higher than 10% of 142
  • Revenue$22 M · higher than 21% of 155
  • Net margin-141.3% · higher than 13% of 144
  • Revenue growth-14.2% · higher than 7% of 104
  • Price / sales0.8× · lower than 91% of 96
  • Price / book2.0× · lower than 62% of 99
  • FCF yield-100.6% · higher than 3% of 76

Peer comparison · Medical Devices

CompanyMarket capP/ENet marginRev. growth
Lifeward Ltd.🇮🇱$17 M—-141.3%-14.2%
Abbott Laboratories🇺🇸$181.1 B38.5×9.8%+5.7%
Medtronic plc🇺🇸$121.2 B23.2×13.9%+8.4%
Stryker Corporation🇺🇸$116.5 B32.2×13.8%+11.2%
Boston Scientific Corporation🇺🇸$66.2 B18.9×16.6%+19.9%
Edwards Lifesciences Corporation🇺🇸$52.8 B51.7×15.3%+11.6%
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳$27.8 B23.6×24.4%—
STERIS plc🇮🇪$20.4 B24.6×13.4%+8.7%
Zimmer Biomet Holdings, Inc.🇺🇸$18.2 B23.8×8.9%+7.2%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Lifeward Ltd.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Lifeward Ltd.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Lifeward Ltd.? Suggest a correction